Comment on "Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"-Reference-Cited by-同舟云学术

Comment on "Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"

Published:2023-04-15 Issue:5 Volume:46 Page:509-512
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Kuss Oliver^ORCID,Rathmann Wolfgang

Funder

Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-023-01292-6.pdf

Reference4 articles.

1. Alkabbani W, Pelletier R, Beazely MA, Labib Y, Quan B, Gamble JM. Drug-drug interaction of the sodium glucose co-transporter 2 inhibitors with statins and myopathy: a disproportionality analysis using adverse events reporting data. Drug Saf. 2022;45:287–95. https://doi.org/10.1007/s40264-022-01166-3.

2. Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol. 2007;64:489–95. https://doi.org/10.1111/j.1365-2125.2007.02900.x.

3. Ihle P, Dippel FW, Schubert I. Statin-associated myopathy. Assessment of frequency based on data of all statutory health insurance funds in Germany. Pharmacol Res Perspect. 2018;6(3):e00404. https://doi.org/10.1002/prp2.404.

4. Kuss O, Rathmann W. A missed protective drug-drug interaction of DPP-4 inhibitors and statins on myopathy risk. Acta Diabetol. 2020;57(1):113–4. https://doi.org/10.1007/s00592-019-01440-4.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Author’s Reply to Kuss and Rathmann’s Comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data”;Drug Safety;2023-04-15